Today announced a study collaboration with Merck, headquartered in Whitehouse Station, N Skin Care .J., to recognize and develop compounds that modulate O-connected N-acetylglucosaminidase an enzyme that’s believed to be involved in the advancement of Alzheimer’s disease and potentially other disorders. The agreement provides Merck with a worldwide, exclusive license to analyze, develop and commercialize compounds that modulate this target. Under the terms of the contract, Merck offers paid Alectos an upfront payment and will fund research to add research of Alectos’ existing portfolio of compounds targeting Alzheimer’s disease.
The ACO Summit, which has been kept at the Hyatt Regency on Capitol Hill in Washington, DC, will bring together leading political, business, and healthcare professionals to supply in-depth insights into accountable care and healthcare reform through innovative technology and strategies. Khan's keynote address, she will demonstrate how real-time, evidence-based decision support and analytics may empower clinicians to create informed decisions about their patients and patient populations at the idea of care. Furthermore, Dr. Khan shall examine how predictive analytics allows ACOs to recognize and treat high-risk patients, improve patient care and avoid costly re-admissions. Following the keynote at 9:20 a.m., Dr. Khan will moderate a panel of sector leaders in the ACO market who’ll discuss real case study examples of effectively implementing predictive analytics for populace health administration.